Abstract
Tiotropium is the first long-acting anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease. There is now evidence that it improves key clinical outcomes. Doctors need to decide how this evidence base should influence clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.